Sponsored by :

With the support of:

Organized by :

The programme of BioData2009 will come later in the year.

Tuesday, January 22

Welcome Introduction and Official Opening Address

• Herve de Kergrohen, Chairman

Official Opening Introduction

• Pierre-François Unger, President of the Geneva State Government and Minister in Charge of the Economy    and Health

• Lionel Eperon, President, BioAlps
• Roger Vioud, Chairman of the International  Commission of the Regional Council of Rhône-Alpes

• François Naef, Member of the Executive

Management  Board, Merck Serono

Interactive session – “European Biotech: Is it better than it looks?”

German biotech stocks have witnessed tough times in 2007. In particular, the disaster of GPC Biotech with the denied approval of its cancer drug Satraplatin was seen as a severe setback for the entire German biotech industry and caused a massive sell-off. Larger financing rounds, not to talk about IPOs, have become increasingly difficult to realize. Other markets have fared better but stocks are nevertheless undervalued as well. However, this gloomy picture veils the fact, that a number of companies have recently made significant progress with maturing clinical pipelines, valuable partnering deals and takeover bids. In this context, are the majority of European biotechs trading now below their fair value? Which catalysts could improve sentiment in the near future throughout Europe? Which factors could catalyse improved market sentiment throughout Europe in the near future?

Moderator

• Raimund Gabriel, Partner, MC Services

Panellists

• Kai Brüning, Senior Portfoliomanager, Deka   Investment
• François Conquet, Early Stage Licensing Director,
Merck Serono
• Uli Kinzel, Director, Nomura Code

• Simon Moroney, CEO, Morphosys
• Gilles Nobécourt, Partner, Edmond de Rotschild          Investment Partners, Life Sciences Team

Interactive session – “Listing Strategies in Europe : Lessons learned”

Over the last three years the UK has seen a diminishing number of biotech companies listing on either the main list or AIM. Of these, 95% headed to the AIM, where they have underperformed. City scuttlebutt is that next year there will be no IPO market in the UK and secondary rounds will be slim, at best. On the other hand, Italian companies have chosen the SWX. The choice of a stock market can become a critical issue for any biotech companies. What lessons have been learned?
Which European stock exchange should a biotech company choose for an IPO? Are we witnessing the emergence of a two class system with Alternext for start-up companies and the SWX with more mature companies? Do different stock exchanges offer differences in valuation? Should European companies envisage double listing in Europe?

Moderator

• Shaun Brown, Director, Innovator Capital Limited

Panellists

• Georges-David Medina, Funding Partner, Hinvest Partners
• Yvonne Wegmann-Günsch, Head of Issuer and Investor Relations, SWX
• Georges-David Medina, BioNest

Wednesday, January 23

Key Note presentation

“ Russia : the emergence of a new biotech market?“

The Government of Moscow has decided to actively support innovation and has financed hundreds of technology projects. The next step is to channel these projects into an industrialisation phase through increased entrepreneurship. While the Russian economy is dominated by its natural energy sector, this willingness is noteworthy as it means that many technologies in cleantech medtech and biotechnology are now open to Russian and foreign funding. Moscow is also at the core of a very large untapped market for new drugs, vaccines and medical technologies. The population is eager to reach Western standards in medicine and in disease prevention as the GDP growth far outpaces that seen in the West. BioData is proud to open up its forum to Russian representatives, as first in many instances.

• Suren Vardanian, Director General, Moscow Agency for Export and Investment Promotion

Analyst Panel Discussion - ”Which stocks to watch in 2008 and beyond”

The European biotech industry has gained new momentum over the last few years with expanded pipelines, increased revenues, strong interest from pharma and good IPO performance. However, since this summer, valuations have declined steadily to the extent that most stocks are largely undervalued. Which European and US biotech and medtech companies are most likely to be the first ones to benefit from an upward change in current trends?

Moderator

• Hervé de Kergrohen, Chairman

Panellists

• René Nordmann, CEO, Medinsight
• Odile Rundquist, Pharmaceutical & Biotech Analyst –Equity Brokerage, Vontobel
• Raghuram Selvaraju, Biotech & Equity Analyst, Rodman & Renshaw

FIRST TUESDAY

Interactive sessions

Interactive session – Switzerland “How to value

innovation?”

Valuating innovation remains a challenge for both private and public companies. How many listed companies in Switzerland are trading below their IPO value today, despite significant progress in their R&D pipeline and increased cash position? Many argue that putting a value on early stage companies remains largely a gamble. On the other hand a number of trade sales and acquisitions of biotech companies by large pharma companies have demonstrated that innovation has tremendous value and can be highly cash generative. Is this gap widening? Is it only a buyers market? Is it possible to value innovation at a fair price? How can companies increase the valuation of their innovation?

Moderator

• Alexandre Müller, Senior Consultant, Dynamics Group

Panellists

• Tim Dyer, CFO, Addex
• Andrew Galazka, Senior VP Autoimmune and Emerging Therapeutic Areas, Merck Serono
• Jesus Martin Garcia, Founder and Managing Partner, Eclosion

• Claudia Gutjahr-Loeser, Senior Director, Head of Corporate Communications and Investor Relations, Morphosys
• Alice Huxley, CEO, Speedel

Medtech panel – “Medtech companies: a new

momentum in BioAlps and Rhône–Alpes region?”

Europe is a major source of innovation in the medical technology field. Historically, the development of new surgical procedures has been easier in Europe because of friendlier regulations than those of the FDA. Large companies such as Siemens and Philips in imaging and Synthes Stratec, Smith and Nephews or Aesculap in orthopedics provide great support for the development of new technologies in Europe. But technology hubs such as Grenoble have also produced breakthroughs such as targeted radiotherapy, computer-assisted surgery and robotics and neurosurgical navigation. These products are now sold by companies such as Varian or Medtronic, proving that European technology continues to be state of the art. The medtech sector is increasingly seen by venture capital as an opportunity. This should benefit many start-up companies in Rhône-Alpes and Western Switzerland

Moderator
• Hervé de Kergrohen, CEO, Praxim

Panellists

• Richard Borgy, Medical Device Specialist, Bri

• Eric Perouse, General Manager, Perouse
• Marie-José Plique, General Manager France, MedCPartners